Amneal Pharmaceuticals (NYSE:AMRX) Stock Price Up 2%

Amneal Pharmaceuticals, Inc. (NYSE:AMRXGet Rating) shares traded up 2% during mid-day trading on Friday . The company traded as high as $2.13 and last traded at $2.09. 11,850 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 831,008 shares. The stock had previously closed at $2.05.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. The Goldman Sachs Group cut their target price on Amneal Pharmaceuticals from $4.50 to $4.00 and set a “buy” rating on the stock in a report on Monday, August 8th. TheStreet cut Amneal Pharmaceuticals from a “c-” rating to a “d+” rating in a research note on Friday, August 12th. Finally, StockNews.com lowered Amneal Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 24th.

Amneal Pharmaceuticals Stock Performance

The business has a fifty day moving average price of $2.46 and a 200-day moving average price of $2.99. The company has a quick ratio of 1.03, a current ratio of 1.56 and a debt-to-equity ratio of 15.38. The stock has a market capitalization of $631.33 million, a P/E ratio of -2.38, a P/E/G ratio of 0.14 and a beta of 1.29.

Amneal Pharmaceuticals (NYSE:AMRXGet Rating) last released its quarterly earnings results on Friday, August 5th. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.03). Amneal Pharmaceuticals had a negative net margin of 6.29% and a positive return on equity of 56.26%. The firm had revenue of $559.40 million for the quarter, compared to analysts’ expectations of $534.44 million. During the same quarter in the prior year, the business earned $0.23 EPS. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, sell-side analysts expect that Amneal Pharmaceuticals, Inc. will post 0.65 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. First Quadrant LLC CA acquired a new stake in Amneal Pharmaceuticals during the 1st quarter worth about $37,000. O Shaughnessy Asset Management LLC acquired a new position in Amneal Pharmaceuticals in the 2nd quarter worth about $37,000. Running Point Capital Advisors LLC acquired a new position in Amneal Pharmaceuticals in the 1st quarter worth about $42,000. Meeder Asset Management Inc. purchased a new stake in Amneal Pharmaceuticals during the 1st quarter worth approximately $62,000. Finally, Sei Investments Co. increased its stake in Amneal Pharmaceuticals by 17.7% during the 1st quarter. Sei Investments Co. now owns 20,553 shares of the company’s stock worth $62,000 after buying an additional 3,096 shares in the last quarter. 32.93% of the stock is currently owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Company Profile

(Get Rating)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Read More

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.